Patents by Inventor Mahmoud Mirmehrabi

Mahmoud Mirmehrabi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polymorphic forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
    Patent number: 11938101
    Abstract: Disclosed herein are polymorphic and amorphous forms of anhydrate, hydrate, and solvates of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide and methods of using such compositions for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging. Further disclosed are methods of making such polymorphic and amorphous forms.
    Type: Grant
    Filed: March 10, 2022
    Date of Patent: March 26, 2024
    Assignee: PTC THERAPEUTICS, INC.
    Inventors: Paul Mollard, Peter Giannousis, Shazad Suchit, Mahmoud Mirmehrabi, Christopher R. Cornell, Kieron E. Wesson
  • POLYMORPHIC FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)BUTANAMIDE
    Publication number: 20230364029
    Abstract: Disclosed herein are polymorphic and amorphous forms of anhydrate, hydrate, and solvates of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide and methods of using such compositions for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging. Further disclosed are methods of making such polymorphic and amorphous forms.
    Type: Application
    Filed: July 5, 2023
    Publication date: November 16, 2023
    Inventors: Paul MOLLARD, Peter GIANNOUSIS, Shazad SUCHIT, Mahmoud MIRMEHRABI, Christopher R. CORNELL, Kieron E. WESSON
  • CRYSTALLINE FORMS OF SOMATOSTATIN MODULATORS
    Publication number: 20220267295
    Abstract: Described herein are pharmaceutically acceptable salts of a somatostatin modulator, crystalline forms of the pharmaceutically acceptable salts of the somatostatin modulator, methods of making such salts and crystalline forms, pharmaceutical compositions and medicaments comprising such salts and crystalline forms, and methods of using such salts and crystalline forms in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
    Type: Application
    Filed: July 15, 2020
    Publication date: August 25, 2022
    Inventors: Jayachandra P. REDDY, Yuxin ZHAO, Mahmoud MIRMEHRABI, Alex MAYO, Madhukar KOTA, Uttam DASH, Vijaykumar Umesh NAIK, Praveen Kumar BANDARU, Yuanqing FANG
  • POLYMORPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)BUTANAMIDE
    Publication number: 20220265578
    Abstract: Disclosed herein are polymorphic and amorphous forms of anhydrate, hydrate, and solvates of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide and methods of using such compositions for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging. Further disclosed are methods of making such polymorphic and amorphous forms.
    Type: Application
    Filed: March 10, 2022
    Publication date: August 25, 2022
    Inventors: Paul Mollard, Peter Giannousis, Shazad Suchit, Mahmoud Mirmehrabi
  • CRYSTALLINE FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL)PIPERAZINE-1-CARBONYL)PHENYL)QUINOLINE-8-SULFONAMIDE
    Publication number: 20220220093
    Abstract: Provided herein are amorphous and crystalline hemisulfate salt forms of the formula. Also provided are pharmaceutical compositions comprising the amorphous and crystalline hemisulfate salt forms, methods for their manufacture, and uses thereof for treating conditions associated with pyruvate kinase such as e.g., pyruvate kinase deficiency.
    Type: Application
    Filed: January 14, 2022
    Publication date: July 14, 2022
    Inventors: Jacob P. Sizemore, Liting Guo, Mahmoud Mirmehrabi, Yeqing Su
  • Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
    Patent number: 11304914
    Abstract: Disclosed herein are polymorphic and amorphous forms of anhydrate, hydrate, and solvates of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide and methods of using such compositions for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging. Further disclosed are methods of making such polymorphic and amorphous forms.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: April 19, 2022
    Assignee: PTC Therapeutics, Inc.
    Inventors: Paul Mollard, Peter Giannousis, Shazad Suchit, Mahmoud Mirmehrabi
  • Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
    Patent number: 11254652
    Abstract: Provided herein are amorphous and crystalline hemisulfate salt forms of the formula (I). Also provided are pharmaceutical compositions comprising the amorphous and crystalline hemisulfate salt forms, methods for their manufacture, and uses thereof for treating conditions associated with pyruvate kinase such as e.g., pyruvate kinase deficiency.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: February 22, 2022
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Jacob P. Sizemore, Liting Guo, Mahmoud Mirmehrabi, Yeqing Su
  • SOLID FORMS OF 2-(3,5-DICHLORO-4-((5-ISOPROPYL-6-OXO-1,6-DIHYDROPYRIDAZIN-3-YL)OXY)PHENYL)-3,5-DIOXO-2,3,4,5-TETRAHYDRO-1,2,4-TRIAZINE-6-CARBONITRILE
    Publication number: 20210122740
    Abstract: The present invention is directed to morphic forms, co-crystals, salts, and amorphous solid dispersions of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile.
    Type: Application
    Filed: July 2, 2019
    Publication date: April 29, 2021
    Inventors: Mahmoud MIRMEHRABI, Marco JONAS, Pavan Karthik BATCHU
  • PROCESS OF MAKING SOMATOSTATIN MODULATORS
    Publication number: 20210087165
    Abstract: Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
    Type: Application
    Filed: December 9, 2020
    Publication date: March 25, 2021
    Inventors: Jayachandra P. REDDY, Mahmoud MIRMEHRABI, Madhukar KOTA, Uttam DASH, Jian ZHAO, Yunfei ZHU
  • POLYMORPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)BUTANAMIDE
    Publication number: 20210015765
    Abstract: Disclosed herein are polymorphic and amorphous forms of anhydrate, hydrate, and solvates of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide and methods of using such compositions for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging. Further disclosed are methods of making such polymorphic and amorphous forms.
    Type: Application
    Filed: July 1, 2020
    Publication date: January 21, 2021
    Inventors: Paul MOLLARD, Peter GIANNOUSIS, Shazad SUCHIT, Mahmoud MIRMEHRABI
  • Process of making somatostatin modulators
    Patent number: 10889561
    Abstract: Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: January 12, 2021
    Assignee: CRINETICS PHARMACEUTICALS, INC.
    Inventors: Jayachandra P. Reddy, Mahmoud Mirmehrabi
  • CRYSTALLINE FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL)PIPERAZINE-1-CARBONYL)PHENYL)QUINOLINE-8-SULFONAMIDE
    Publication number: 20200277279
    Abstract: Provided herein are amorphous and crystalline hemisulfate salt forms of the formula (I). Also provided are pharmaceutical compositions comprising the amorphous and crystalline hemisulfate salt forms, methods for their manufacture, and uses thereof for treating conditions associated with pyruvate kinase such as e.g., pyruvate kinase deficiency.
    Type: Application
    Filed: November 21, 2018
    Publication date: September 3, 2020
    Inventors: Jacob P. Sizemore, Liting Guo, Mahmoud Mirmehrabi, Yeqing Su
  • Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
    Patent number: 10751302
    Abstract: Disclosed herein are polymorphic and amorphous forms of anhydrate, hydrate, and solvates of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide and methods of using such compositions for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging. Further disclosed are methods of making such polymorphic and amorphous forms.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: August 25, 2020
    Assignee: PTC Therapeutics, Inc.
    Inventors: Paul Mollard, Peter Giannousis, Shazad Suchit, Mahmoud Mirmehrabi
  • PROCESS OF MAKING SOMATOSTATIN MODULATORS
    Publication number: 20200048219
    Abstract: Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
    Type: Application
    Filed: October 3, 2019
    Publication date: February 13, 2020
    Inventors: Jayachandra P. REDDY, Mahmoud MIRMEHRABI, Madhukar KOTA, Uttam DASH, Jian ZHAO, Yunfei ZHU
  • Crystalline and amorphous forms of 17-alpha-hydroxyprogesterone caproate
    Patent number: 10556922
    Abstract: The disclosure is in part directed to crystalline forms of 17-?-hydroxyprogesterone caproate and variants thereof.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: February 11, 2020
    Assignee: AMAG PHARMACEUTICALS, INC.
    Inventor: Mahmoud Mirmehrabi
  • Process of making somatostatin modulators
    Patent number: 10464918
    Abstract: Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: November 5, 2019
    Assignee: CRINETICS PHARMACEUTICALS, INC.
    Inventors: Jayachandra P. Reddy, Mahmoud Mirmehrabi, Madhukar Kota, Uttam Dash
  • POLYMORPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)BUTANAMIDE
    Publication number: 20190307706
    Abstract: Disclosed herein are polymorphic and amorphous forms of anhydrate, hydrate, and solvates of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide and methods of using such compositions for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging. Further disclosed are methods of making such polymorphic and amorphous forms.
    Type: Application
    Filed: March 14, 2019
    Publication date: October 10, 2019
    Inventors: Paul MOLLARD, Christopher R. CORNELL, Kieron E. WESSON, Peter GIANNOUSIS, Shazad SUCHIT, Mahmoud MIRMEHRABI
  • PROCESS OF MAKING SOMATOSTATIN MODULATORS
    Publication number: 20190218202
    Abstract: Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
    Type: Application
    Filed: January 16, 2019
    Publication date: July 18, 2019
    Inventors: Jayachandra P. REDDY, Mahmoud MIRMEHRABI, Madhukar KOTA, Uttam DASH, Jian ZHAO, Yunfei ZHU
  • Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
    Patent number: 10251847
    Abstract: Disclosed herein are polymorphic and amorphous forms of anhydrate, hydrate, and solvates of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide and methods of using such compositions for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging. Further disclosed are methods of making such polymorphic and amorphous forms.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: April 9, 2019
    Assignee: BIOELECTRON TECHNOLOGY CORPORATION
    Inventors: Paul Mollard, Christopher R. Cornell, Kieron E. Wesson, Peter Giannousis, Shazad Suchit, Mahmoud Mirmehrabi
  • CRYSTALLINE AND AMORPHOUS FORMS OF 17-ALPHA-HYDROXYPROGESTERONE CAPROATE
    Publication number: 20180282366
    Abstract: The disclosure is in part directed to crystalline forms of 17-?-hydroxyprogesterone caproate and variants thereof.
    Type: Application
    Filed: September 29, 2016
    Publication date: October 4, 2018
    Inventor: Mahmoud MIRMEHRABI